top of page

ABOUT US

GrayMatters Health Header

WHO IS GMH?

GMH is the first company to develop a treatment based on a digital biomarker of brain activity associated with mental health disorders. 

The biomarker, named EEG-fMRI-Pattern, or EFP, is based on advanced statistical models that register brain area specific fMRI data to EEG. The company's FDA-cleared device, Prism for PTSD, uses the amygdala-based biomarker with an interactive computer simulation to help patients gain control, or agency, of their PTSD symptoms. 

GMH is collaborating with key medical institutions to explore applying an EFP biomarker to treat mental disorders beyond PTSD. A pivotal study is underway to evaluate an EFP for Major Depressive Disorder (MDD) at McLean Hospital, Harvard University's large Psychiatric Hospital. 

In addition, using deidentified data collected from treatments, our team of experts is developing therapy predictors, patient management tools and treatment personalization into the Prism platform. 

OUR TEAM

Prof. Talma Hendler, MD, PhD

Prof. Talma Hendler, MD, PhD

Inventor, SAB Chairperson,

Chief Medical Scientist

Oded Kraft

Oded Kraft

CEO, President

Co-founder

Rani Cohen

Rani Cohen

Executive Chairman BOD,

Co-founder

Shai Attia

Shai Attia

VP R&D , Co-founder

Adar Shani

Adar Shani

VP Clinical,

Regulatory & Quality Affairs

Dr. Aron Tendler

Dr. Aron Tendler

Chief Medical Officer

Kirk Thelander

Kirk Thelander

Chief Commercial Officer

Pam Schwartz

Pam Schwartz

VP Marketing

AWARDS

Edison gold Prism.jpg
Red Herring Europe Winner 100
Nature awards.jpg
MIC_InstaPost.jpg
HIT Innovator.jpg
Best Startup Award 2023

Best Startup Award 2023

SelectUSA Investor Summit Medtech track

OUR PARTNERS

Otsuka Medical Device Co., Ltd Logo
Sheba Logo
g-tec Logo
Mclean Logo
ברזילי Logo
באר-יעקב Logo
Bird-foundation Logo
TLV Souraski medical center Logo
RAMBAM Logo
5-ht-de-hub Logo
Dehub Logo
European Innovation Council
bottom of page